The percentage of patients with confirmed DVT and major postoperative bleeding (respectively) was: 14.9% and 1.5% for enoxaparin 40 mg; 4.7% and 4.2% for enoxaparin 30 mg and 11.6% and 6.2% for heparin.
The rate of DVT was significantly lower in the enoxaparin 30 mg group than for heparin (p<0.5) but not different for those patients who received enoxaparin 40 mg (p=0.33). The incidence of major bleeding was lower in the enoxaparin 40 mg group than for heparin (p<0.05), but not statistically different from those patients receiving enoxaparin 30 mg (p=0.72).